Understanding how a common lung cancer mutation triggers immune responses
Official title: Defining features of the neoantigen-specific T cell response against a common EGFR mutation in lung cancer
Funded at Case Western Reserve University · NIH-10995102 · Data updated 2026-11-12
This study is looking at how a specific change in the EGFR gene, common in lung cancer, can help the immune system recognize and fight cancer cells, which could lead to new treatments for lung cancer patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $53,974 |
| NIH project number | 1F30CA294669-01 |
| Project ID | NIH-10995102 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are lung cancer patients who have been diagnosed with the EGFR L858R mutation.
✕Less likely to help
Patients without the EGFR L858R mutation or those with other types of lung cancer may not benefit from this research.
What this research studies
This research investigates how the L858R mutation in the EGFR gene, which is prevalent in lung cancer, can stimulate the immune system to attack cancer cells. By analyzing the interaction between mutation-derived peptides and T cells, the study aims to uncover the mechanisms that enable the immune system to recognize and respond to this specific mutation. The approach includes characterizing the binding of these peptides to HLA complexes and assessing their ability to activate CD8+ T cells. This could lead to insights into developing targeted immunotherapies for lung cancer patients.
Why it matters
Potential benefit: If successful, this research could enhance the development of personalized immunotherapies for lung cancer patients with the EGFR L858R mutation.
How similar studies have gone: Previous research has shown promising results in targeting neoantigens for cancer immunotherapy, indicating that this approach has potential for success.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Wang, Stephen Lee — Case Western Reserve University
- Study coordinator: Wang, Stephen Lee
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.